Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company focused on developing innovative therapies for cancer. The company's proprietary INTASYL® technology platform utilizes self-delivering RNAi (RNA interference) to silence specific genes implicated in the proliferation of solid tumors. This technology, derived from Nobel Prize-winning research, is unique in its ability to make immune cells more effective in killing tumor cells without the need for specialized formulations or drug delivery systems.

Phio is currently conducting a Phase 1b clinical trial for its lead compound, PH-762, which silences the PD-1 protein that inhibits T cells' ability to kill cancer cells. The company is also exploring the potential applications of INTASYL for other chronic diseases and disorders, including dermatological conditions, and seeks collaborative partnerships for product development. Phio's mission is to develop siRNA therapies that enable the body's own defenses to overcome cancer in novel ways.

Phio Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative siRNA therapies that harness the body's own immune system to fight cancer. Their mission is to create new pathways towards a cancer-free future by developing their patented siRNA therapies that enable the body's own defenses to overcome cancer in ways others cannot.

Phio Pharmaceuticals fosters a culture of innovation and collaboration, driven by a shared passion for developing groundbreaking siRNA therapies to combat cancer. Their dedication to precision medicine and scientific excellence is evident in their team of experienced professionals and their commitment to building a diverse and inclusive workplace. Phio's culture is one of forward-thinking ambition, where team members are encouraged to contribute their unique perspectives and work together to achieve their shared vision of a cancer-free future.